Fresenius Kabi in talks to buy Akorn

By Gareth Macdonald contact

- Last updated on GMT

iStock/macgyverhh
iStock/macgyverhh

Related tags: U.s. securities and exchange commission, Fresenius kabi

Akorn Inc is in takeover talks with German injectable drug specialist Fresenius SE & Co. KGaA.

The US generic drug manufacturer confirmed the talks in a US Securities and Exchange Commission (SEC) filing​ today.

Similarly, Fresenius said​ discussions are ongoing.

A spokesman for the German firm told us "Fresenius Kabi is currently in discussions with Akorn, Inc. concerning a potential acquisition​."

He declined to comment further.

Related news

Show more

Related products

show more

The battle of performance in pharma production

The battle of performance in pharma production

Telstar Life Science Solutions | 26-Mar-2019 | Case Study

Telstar case study. Discover how a versatile freeze-dryer automatic loading & unloading systemDiscover how a versatile freeze-dryer automatic loading...

From Candidate to Clinic- European Capabilities

From Candidate to Clinic- European Capabilities

Catalent Pharma Solutions | 22-Oct-2018 | Technical / White Paper

Catalent’s Nottingham, UK facility focuses on early stage development of small molecule drug candidates from the bench to clinic. This facility offers...

Fill Release at the Right Time in the Right Place

Fill Release at the Right Time in the Right Place

Gelita AG | 19-Sep-2018 | Technical / White Paper

From rapid release in the stomach for e.g. analgesics to enteric release for fills with unpleasant aftertaste – GELITA delivers the respective gelatine...

Accelerate your supply chain as pressures intensify

Accelerate your supply chain as pressures intensify

William Reed | 17-Sep-2018 | Technical / White Paper

Food, Drink and Non-Food manufacturers are under pressure. Range reviews, massive retail mergers, the backlash against plastic packaging and the ongoing...

Related suppliers

Follow us

Products

View more